Announcement of the clinical data of the new conjugation drug VDC!

Article source: Medical Rubik's Cube Pro

Author: Haimer

On November 15, American biopharmaceutical company Aura Biosciences announced its first virus-like drug conjugate (VDC) drug AU-011 in uncertain lesions (IL) and choroidal melanoma (choroidal melanoma, CM).

Aura was founded in 2009 and is headquartered in Massachusetts, USA, dedicated to the development of targeted therapies for ophthalmic tumors and urinary system tumors

Aura's virus-like particle (VLP)-based technology platform enables the covalent binding of VLP to cytotoxic drugs to obtain VDC, which can selectively bind to heparan sulfate proteoglycan (HSPG) on the surface of solid tumors without binding to normal tissues.

VLP is coupled with cytotoxic drugs to obtain VDC (Source: Aura official website)

AU-011 is the fastest-growing VDC drug candidate in the Aura pipeline.

AU-011's dual mechanism of killing tumors (Source: Aura official website)

The Phase Ib/II clinical trial of AU-011 evaluated the safety and effectiveness of IVT administration in the treatment of IL and CM

The tumors of most patients are under control (Source: Aura official website)

In terms of safety, AU-011 is generally safe and well tolerated.

Aura stock price on November 15 (Source: Snowball)

On the same day, Aura also announced the Phase II safety results of AU-011 SC administration

Dr.

Note: The original text has been deleted

Reference materials:

[1] Aura Biosciences Presents Final Phase 1b/2 Data for its firstVirus-Like Drug Conjugate, AU-011, in Patients with Choroidal Melanoma at theAmerican Academy of Ophthalmology 2021 Annual Meeting (Source: Aura official website)

[2] The new conjugate drug VDC is here! Aura completed a new round of financing of US$80 million, and its core products are moving towards phase III clinical trials (Source: Medical Rubik's Cube Pro)